S-Space

Browse

Subject

Jump to a point in the index

Or type in a year

Sort by
In order
Results/Page
Authors/record

Showing results 1 to 24 of 24

Issue Date	Title / Author(s) / Citation	File
2009-07	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI Yi, Hyeon Gyu; Kim, Hye Jin; Kim, Yu Jung; Han, Sae-Won; Oh, Do-Youn; Lee, Se-Hoon; Kim, Dong-Wan; Im, Seock-Ah; Kim, Tae-You; Kim, Chul Soo; Heo, Dae Seog; Bang, Yung-Jue Lung Cancer, Vol.65 No.1, pp.80-84	DOI
2010-02	Timing of local and distant failure in resected lung cancer: Implications for reported rates of local failure Boyd, Jessamy A.; Hubbs, Jessica L.; Kim, Dong W.; Hollis, Donna; Marks, Lawrence B.; Kelsey, Chris R. Journal of Thoracic Oncology, Vol.5 No.2, pp.211-214	DOI
2010-03	Expression of Class III Beta-Tubulin Correlates with Unfavorable Survival Outcome in Patients with Resected Non-small Cell Lung Cancer Koh, Youngil; Jang, Bogun; Han, Sae-Won; Kim, Tae-Min; Oh, Do-Youn; Lee, Se-Hoon; Kang, Chang Hyun; Kim, Dong-Wan; Im, Seock-Ah; Chung, Doo Hyun; Kim, Young Tae; Kim, Tae-You; Kim, Young-Whan; Kim, Joo Hyun; Heo, Dae Seog; Bang, Yung-Jue Journal of Thoracic Oncology, Vol.5 No.3, pp.320-325	DOI
2010-06	The relationship between response to previous systemic treatment and the efficacy of subsequent pemetrexed therapy in advanced non-small cell lung cancer Sun, Jong-Mu; Oh, Do-Youn; Lee, Se-Hoon; Kim, Dong-Wan; Im, Seock-Ah; Kim, Tae-You; Lee, Jong Seok; Kim, Young-Whan; Heo, Dae Seog; Bang, Yung-Jue Lung Cancer, Vol.68 No.3, pp.427-432	DOI
2011-03	Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: Correlation with fluorescence in situ hybridization Paik, Jin Ho; Choe, Gheeyoung; Kim, Hyojin; Choe, Ji-Young; Lee, Hyun Ju; Lee, Choon-Taek; Lee, Jong Seok; Jheon, Sanghoon; Chung, Jin-Haeng Journal of Thoracic Oncology, Vol.6 No.3, pp.466-472	DOI
2011-05	Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification Ou, Sai-Hong Ignatius; Kwak, Eunice L.; Siwak-Tapp, Christina; Dy, Joni; Bergethon, Kristin; Clark, Jeffrey W.; Camidge, D. Ross; Solomon, Benjamin J.; Maki, Robert G.; Bang, Yung-Jue; Kim, Dong-Wan; Christensen, James; Tan, Weiwei; Wilner, Keith D.; Salgia, Ravi; Iafrate, A. John Journal of Thoracic Oncology, Vol.6 No.5, pp.942-946	DOI
2012-06	Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer A proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma Paik, Jin Ho; Choi, Chang-Min; Kim, Hyojin; Jang, Se Jin; Choe, Gheeyoung; Kim, Dong Kwan; Kim, Hwa Jung; Yoon, Hoil; Lee, Choon-Taek; Jheon, Sanghoon; Choe, Ji-Young; Chung, Jin-Haeng Lung Cancer, Vol.76 No.3, pp.403-409	DOI
2012-08	Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation Lee, June Koo; Kim, Tae Min; Koh, Youngil; Lee, Se-Hoon; Kim, Dong-Wan; Jeon, Yoon-Kyung; Chung, Doo Hyun; Yang, Seok-Chul; Kim, Young Tae; Kim, Young-Whan; Heo, Dae Seog; Bang, Yung-Jue Lung Cancer, Vol.77 No.2, pp.460-463	DOI
2017-05	Superior Treatment Response and In-field Tumor Control in Epidermal Growth Factor Receptor-mutant Genotype of Stage III Nonsquamous Non-Small cell Lung Cancer Undergoing Definitive Concurrent Chemoradiotherapy Lim, Yu Jin; Chang, Ji Hyun; Kim, Hak-Jae; Keam, Bhumsuk; Kim, Tae Min; Kim, Dong-Wan; Paeng, Jin Chul; Kang, Keon Wook; Chung, June-Key; Jeon, Yoon Kyung; Chung, Doo Hyun; Wu, Hong-Gyun Clinical Lung Cancer, Vol.18 No.3, pp.e169-e178	DOI
2017-10	Pooled systemic efficacy and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small cell lung cancer Yang, James Chih-Hsin; Ou, Sai-Hong Ignatius; De Petris, Luigi; Gadgeel, Shirish; Gandhi, Leena; Kim, Dong-Wan; Barlesi, Fabrice; Govindan, Ramaswamy; Dingemans, Anne-Marie C.; Crino, Lucio; Lena, Nerve; Popat, Sanjay; Ahn, Jin Seok; Dansin, Eric; Golding, Sophie; Bordogna, Walter; Batas, Bogdana; Morcos, Peter N.; Zeaiter, Ali; Shaw, Alice T. Journal of Thoracic Oncology, Vol.12 No.10, pp.1552-1560	DOI
2018-08	Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy Lee, Jong Seok; Lee, Ki Hyeong; Cho, Eun Kyung; Kim, Dong-Wan; Kim, Sang-We; Kim, Joo-Hang; Cho, Byoung Chul; Kang, Jin Hyoung; Han, Ji-Youn; Min, Young Joo; Park, Keunchil Lung Cancer, Vol.122, pp.234-242	DOI
2019-05	Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M-Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report Yang, James Chih-Hsin; Shepherd, Frances A.; Kim, Dong-Wan; Lee, Gyeong-Won; Lee, Jong Seok; Chang, Gee-Chen; Lee, Sung Sook; Wei, Yu-Feng; Lee, Yun Gyoo; Laus, Gianluca; Collins, Barbara; Pisetzky, Francesca; Horn, Leora Journal of Thoracic Oncology, Vol.14 No.5, pp.933-939	DOI
2019-07	Advanced-Stage Non–Small Cell Lung Cancer: Advances in Thoracic Oncology 2018 Remon, Jordi; Ahn, Myung-Ju; Girard, Nicolas; Johnson, Melissa; Kim, Dong-Wan; Lopes, Gilberto; Pillai, Rathi N.; Solomon, Benjamin; Villacampa, Guillermo; Zhou, Qing Journal of Thoracic Oncology, Vol.14 No.7, pp.1134-1155	DOI
2019-09	First-line Pembrolizumab Versus Pembrolizumab Plus Chemotherapy Versus Chemotherapy Alone in Non-small-cell Lung Cancer: A Systematic Review and Network Meta-analysis Kim, Ryul; Keam, Bhumsuk; Hahn, Seokyung; Ock, Chan-Young; Kim, Miso; Kim, Tae Min; Kim, Dong-Wan; Heo, Dae Seog Clinical Lung Cancer, Vol.20 No.5, pp.331-338.e4	DOI
2020-03	Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial Huber, Rudolf M.; Hansen, Karin H.; Paz-Ares Rodriguez, Luis; West, Howard L.; Reckamp, Karen L.; Leighl, Natasha B.; Tiseo, Marcello; Smit, Egbert F.; Kim, Dong-Wan; Gettinger, Scott N.; Hochmair, Maximilian J.; Kim, Sang-We; Langer, Corey J.; Ahn, Myung-Ju; Kim, Edward S.; Kerstein, David; Groen, Harry J. M.; Camidge, D. Ross Journal of Thoracic Oncology, Vol.15 No.3, pp.404-415	DOI
2020-10	Real-World Experience of Nivolumab in Non-small Cell Lung Cancer in Korea Lim, Sun Min; Kim, Sang-We; Cho, Byoung Chul; Kang, Jin Hyung; Ahn, Myung-Ju; Kim, Dong-Wan; Kim, Young-Chul; Lee, Jin Soo; Lee, Jong-Seok; Lee, Sung Yong; Park, Keon Uk; An, Ho Jung; Cho, Eun Kyung; Jang, Tae Won; Kim, Bong-Seog; Kim, Joo-Hang; Lee, Sung Sook; Na, Im-Ii; Yoo, Seung Soo; Lee, Ki Hyeong Cancer Research and Treatment, Vol.52 No.4, pp.1112-1119	DOI
2021-07	Temporal evolution of programmed death-ligand 1 expression in patients with non-small cell lung cancer Nam, Chang Hyun; Koh, Jaemoon; Ock, Chan-Young; Kim, Miso; Keam, Bhumsuk; Kim, Tae Min; Jeon, Yoon Kyung; Kim, Dong-Wan; Chung, Doo Hyun; Heo, Dae Seog The Korean Journal of Internal Medicine, Vol.36 No.4, pp.975-984	DOI
2021-12	Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial Camidge, D. Ross; Kim, Hye Ryun; Ahn, Myung-Ju; Yang, James C. H.; Han, Ji-Youn; Hochmair, Maximilian J.; Lee, Ki Hyeong; Delmonte, Angelo; Campelo, D. h Maria Rosario Garcia; Kim, Dong-Wan; Griesinger, Frank; Felip, Enriqueta; Califano, Raffaele; Spira, Alexander I.; Gettinger, Scott N.; Tiseo, Marcello; Lin, Huamao M.; Liu, Yuyin; Vranceanu, Florin; Niu, Huifeng; Zhang, Pingkuan; Popat, Sanjay Journal of Thoracic Oncology, Vol.16 No.12, pp.2091-2108	DOI
2022-07	Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trial Soo, Ross A.; Tan, Eng Huat; Hayashi, Hidetoshi; Seto, Takashi; Lin, Chia-Chi; Ou, Sai-Hong Ignatius; Kim, Dong-Wan; Liu, Geoffrey; Abbattista, Antonello; Martini, Jean-Francois; Martini, Francois; Wong, Chew Hooi; Toffalorio, Francesca; Solomon, Benjamin J. Lung Cancer, Vol.169, pp.67-76	DOI
2022-12	Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2) Ou, Sai-Hong Ignatius; Nishio, Makoto; Ahn, Myung-Ju; Mok, Tony; Barlesi, Fabrice; Zhou, Caicun; Felip, Enriqueta; de Marinis, Filippo; Kim, Sang-We; Perol, Maurice; Liu, Geoffrey; Migliorino, Maria Rita; Kim, Dong Wan; Novello, Silvia; Bearz, Alessandra; Garrido, Pilar; Mazieres, Julien; Morabito, Alessandro; Lin, Huamao M.; Yang, Hui; Niu, Huifeng; Zhang, Pingkuan; Kim, Edward S. Journal of Thoracic Oncology, Vol.17 No.12, pp.1404-1414	DOI
2023-04	99mTc-MAA accumulation within tumor in preoperative lung perfusion SPECT/CT associated with occult lymph node metastasis in patients with clinically N0 non-small cell lung cancer Murad, Vanessa; Suh, Minseok; Choi, Hongyoon; Cheon, Gi Jeong; Na, Kwon Joong; Kim, Young Tae BMC Cancer, 23(1):381	view file DOI
2023-09	Exploring the past, present, and future of postoperative radiotherapy for N2 stage non-small cell lung cancer Kim, Byoung Hyuck; Kim, Jae Sik; Kim, Hak Jae Radiation Oncology Journal, Vol.41 No.3, pp.144-153	DOI
2023-10	Prognostic utility of body composition parameters based on computed tomography analysis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors Park, Ji Eun; Jo, Jaemin; Youk, Jeonghwan; Kim, Miso; Yoon, Soon Ho; Keam, Bhumsuk; Kim, Tae Min; Kim, Dong-Wan Insights into Imaging, Vol.14 No.1, p. 182	DOI
2024-04	Phase II study investigating the efficacy and safety of glesatinib (MGCD265) in patients with advanced NSCLC containing MET activating alterations Hong, David S.; Cappuzzo, Federico; Chul Cho, Byoung; Dowlati, Afshin; Hussein, Maen; Kim, Dong-Wan; Percent, Ivor; Christensen, James G.; Morin, Josée; Potvin, Diane; Faltaos, Demiana; Tassell, Vanessa; Der-Torossian, Hirak; Chao, Richard Lung Cancer, Vol.190, p. 107512	DOI